Intera Atlas
Run match
Sites / Science 37
Is this you?

Request access for Science 37 with your @science37.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Science 37

Unclaimed profile

DCT Network · Los Angeles, CA (Morrisville, NC - Research Triangle) · ~1 (FDA-inspected Direct-to-Patient Site) sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 4Lift (cardio sample) 0.07Recruit soph 0.43
Quality Scorecard (1–100)
Overall62Recruit65Ops63Sponsor60Ther58

Performance (observed)

Historical trials
113
Completed
46
Terminated/Withdrawn
9
Completion rate
84%
Active now
58
Phase 2
23
Phase 3
78
Realized enrollment
273,055
First study year
2008
Years active
18
Match confidence
high
Enrollment velocity (inf)
15,170

Therapeutic

Areas
Therapeutically agnostic; 200+ trials across Phases I-IV (observational to full clinical)
Specialties
Rare diseases, MDD, respiratory, oncology, vascular disorders
Breadth (conditions)
150
States
All 50 states

Recruitment (web observed)

Trial Finder
Yes
Patient database
N
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y (blog, case studies)
Capability notes
Direct-to-patient recruitment, 86% completion rate, 20-30% of trial enrollment as single site, 50-state medical licensure, 150+ research-grade nurses

Relationships

Sponsors
Merck Sharp & Dohme LLC; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases (NIAID); Novo Nordisk A/S; Janssen Research & Development, LLC; Bayer
CROs
Parexel
Partnerships
Tufts CSDD (published landmark study)
Owner / parent
Public (NASDAQ: SNCE, IPO 2021), $46.8M market cap, $70.1M annual revenue
Expansion
Morrisville NC, Los Angeles CA headquarters

Capacity & people

Investigators
—
Coordinators
—
CEO
Tyler Van Horn (appointed January 2025)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Darcy Forman (Chief Delivery Officer)
Emails
Unknown

Tech & DCT

eSource
Yes
eConsent
Yes
Uses AI
Yes
Builds tech
Builds Tech Internally
Home visits
Y (150+ research-grade nurses)
DCT / decentralized
Y (Direct-to-Patient model, 50-state licensure, FDA-inspected)
Tech stack
Proprietary SaaS platform for decentralized trial orchestration (Science 37 Technology Platform), Metasite virtual site model, eCOA, telemedicine, wearables integration
Recruiting visible
Y

Notes

Pure-play DCT platform with single virtual site, 50-state reach. Innovative technology (SaaS platform, Metasite model), strong patient-centric approach, FDA-inspected with NAI classification. However: no traditional owned/managed sites (not a site network per ICP definition), likely has sophisticated in-house recruitment tech, public company may be slower to close. Borderline fit - good for DCT integration pilots but lacks site network structure.

Recommendation features (sample indication)

Ind fit 0.12Liftability 0.07Overall62

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.